Despite the great progress in breast cancer research and treatment, measures for efficient targeting of triple-negative breast cancer (TNBC) are still lacking. The well-established dependency of cancer cells on their microenvironment suggests that targeting the tumor niche might form a novel therapeutic approach. We identified the tumor-associated macrophage (TAM) infiltration in breast cancer tissues by immunohistochemistry, and analyzed overall survival (OS). U937 co-cultures with MDA-MB-231, MDA-MB-468 and MCF-7, respectively, to simulate in vivo cellular interactions were assessed. In hormone-independent breast cancer cell conditioned media (CM), U937 differentiates into M2 macrophage as identified by morphological changes and expression of specific surface antigens CD163 and CD204. Moreover, MDA-MB-231 recruits U937, and colony-stimulating factor 1 (CSF1) level in MDA-MB-231 and MDA-MB-468 CM is much higher than that of MCF-7. Overexpression of CSF1 in MCF-7 fails to rebuild its aggressiveness both in vitro and in vivo since CSF1 was not found extracellularly, while genetic inhibition of CSF1 in MDA-MB-231 abrogates TAM infiltration and consequently reduces tumorigenesis in non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. Using various strategies we demonstrate that CSF1-induced TAMs specifically support breast cancer progression. Importantly, our results may reveal the efficacy of using targeted therapy against tumor niche and indicate that CSF1 inhibition may limit some breast cancer progression.
Introduction
In the most recent 5 years, delay-adjusted cancer incidence rates declined by 1.8% per year in men and were stable in women, while cancer death rates nationwide decreased by 1.8% per year in men and by 1.4% per year in women in the United States (1) . However, breast cancer is still one of the most frequently diagnosed cancers in women and the leading cause of cancer-related death among women worldwide, including China, and also one of the leading causes of disease-associated death among women. Despite the great progress that has been made in breast cancer research and treatment, measures for efficient targeting triple-negative breast cancer (TNBC) are still unavailable. Colony-stimulating factor 1 (CSF1), also known as macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types, and is involved in the proliferation, differentiation and survival of monocytes, macrophages and bone marrow progenitor cells (2, 3) . The active form of CSF1 is found extracellularly as a disulfide-linked homodimer, and has been reported to be correlated with poor prognosis in many cancers (4) . It is reported that about one in eight women in the United States will develop invasive breast cancer over the course of their lifetime, and TNBC is one subtype with the poorest prognosis, which accounts of 15-25% breast cancers (1) . Metastasis is a far from known, complex, multi-step process, including at least these six steps: tumor cell invasion of the basement membrane, intravasation into the vascular or lymphatic system, survival in the blood circulation or lymph nodes, attachment to the blood vessel wall and extravasation to the target organ, followed by subsequent colonization and aggressive growth to form a macrometastasis under a favorable microenvironment (5) . Each step makes cancer metastasis an almost impossible mission. However, in clinical practice, a number of subjects with early-stage breast cancer even die from relapse or metastasis, regardless of the intensive adjuvant therapy given. Substantial efforts have been made in understanding the molecular mechanisms of the disease and applying adjuvant therapy to decrease the probabilities of relapse and metastasis, such as targeted therapy and endocrine therapy; however, there is no such an effective measure to patients with TNBC. The role of tumor microenvironment (TME) during the initiation and progression of breast cancer is now realized to be of great importance, both for the understanding of breast cancer biology and exploiting new molecular targets for breast cancers. Macrophage is a major component of TME, and its infiltration is not an uncommon phenomenon in cancer tissues. Normally, these macrophages are called tumor-associated macrophages (TAMs), which share properties of alternatively activated macrophage (M2) phenotype (6) . Reports indicate that the prevalence of TAM infiltration correlates with poor prognosis in some cancer patients indicating a macrophage-supporting role for tumor progression (7, 8) . However, the exact mechanisms involved are still ambiguous.
Macrophage originates from the mononuclear phagocytic lineage, whose polarization is dependent on the cytokines in the microenvironment. The classical activation (M1) is triggered by T helper 1 (Th1) cytokines, such as interferon-γ, bacterial lipopolysaccharide (LPS) and TNF-α. In contrast, the alternative activation (M2) is induced by T helper 2 (Th2) cytokines, like IL-4, IL-13 and CSF1 (M-CSF) (9, 10) . Classical or M1 activation mediates the defense against bacterial pathogens, and secretes high levels of IL-12 and low levels of IL-10, whilst alternative or M2 activation has a ʻpro-tumorigenicʼ effect by producing high levels of IL-10, TGF-β and low levels of IL-12. TAMs present the M2 phenotype in TME, and seem to actively promote tumor growth (11, 12) . TAMs differentiate from circulating monocytes that leave the vasculature and enter the tumor tissue in response to a variety of cues secreted from the tumor and also in response to TME. Once there, they have been shown to promote angiogenesis, tumor growth, invasion and metastasis through secretion of cytokines to coordinate tumor-promoting immune responses as well as through secretion of tissue-remodeling cysteine cathepsin proteases (13) .
In this study, the objective was to examine whether CSF1 level and TAM infiltration correlates with breast cancer hormone receptor status, which influences treatment measures and cancer prognosis. Further, to clarify the mechanism involved may usher in an era of new treatment for CSF1 expression breast cancer, especially for those hormone-independent TNBCs with no well-established targeted therapy available.
Materials and methods
Ethics statement. The study involving human participants was approved by the Ethics Committee of Fudan University Shanghai Cancer Center. Written informed consent was obtained from all the patients before the enrollment. All animal protocols were approved by the Animal Care Committee of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (permit no. IBS14-0806). Animals were kept under stable temperature and humidity conditions. All surgery was performed by cervical dislocation to minimize suffering.
Immunohistochemistry. Paraffin-embedded blocks were obtained from the Breast Malignancy Database established by the Department of Breast Surgery, Fudan University Shanghai Cancer Center (Shanghai, China). All of the enrolled patients have fully detailed clinicopathological information and follow-up results. Written informed consent was obtained from the patients before enrollment. We are authorized to use the tissues for research only and have reported the database information previously (14) . For immunohistochemical analysis, 89 paraffin-embedded blocks were cut into 5-µm serial sections, and following the confirmation of breast cancer diagnosis by H&E staining, immunohistochemistry was performed following standard procedures. CD163 antibody (clone 10D6; Novocastra/Leica Microsystems, Newcastle, UK) used for immunostaining was titered to find the optimal concentration (1:100). Sections were counterstained with hematoxylin for the identification of the nuclei. Detection was performed using the Dako Envision System. Images were captured under a microscope with a CCD camera.
Cell culture. Breast cancer cell lines MDA-MB-231, MD-MB-468 and MCF-7 were originally obtained from the American Type Culture Collection (ATCC; Manassas, vA, USA); the human promonocytic cell line U937 originating from the ATCC was kindly provided by Professor Duan Ma (Key Laboratory of Molecular Medicine, Ministry of Education, Shanghai Medical College, Fudan University). All cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and 100 U/ml penicillin/streptomycin (Gibco/Invitrogen, Carlsbad, CA, USA) at 37˚C in a humidified atmosphere of 5% CO 2 .
Lentivirus infected stable cell line generation. MDA-MB-231, MD-MB-468, MCF-7 and U937 cells were transfected with green or red fluorescence protein (GFP or RFP) expressing lentiviral particles (cat. nos. LvP340 and LvP299; GenTarget, Inc., San Diego, CA, USA) according to the manufacturer's instructions. MCF-7 was transfected with GFP with puromycin resistance (GFP-puro)-tagged CSF1-overexpressing lentiviral particles (cat. no. GCK970139; GeneChem Co., Ltd., Shanghai, China), and MDA-MB-231 was transfected with GFP-puro-tagged shRNA lentiviral particles specifically targeting CSF1 (cat. no. ST3071-A; Shanghai SunBio Medical Biotechnology Co., Ltd., Shanghai, China). Briefly, for adhesive cells the cells were seeded in complete medium at appropriate density (at the time of transduction, cells should be 50-75% confluent) and incubated overnight, the medium was removed and fresh warm complete medium was added with appropriate amount of pre-made lentivirus to obtain the desired MOI, then incubated for another 72 h at 37˚C in a humidified atmosphere of 5% CO 2 . For suspension cells, the cells were seeded in complete medium at appropriate density and incubated until density reaching 3x10 6 cells/ml, then cells were diluted into 1x10 6 cells/ml with fresh warm complete medium and appropriate amount of pre-made lentivirus was added to obtain the desired MOI, incubated for 24 h at 37˚C in a humidified atmosphere of 5% CO 2 with a shaking flask, then an equal amount of fresh medium containing relevant antibiotics was added for another 48 h. Positive transduction of cells were visualized by fluorescence microscopy and isolated by fluorescence-activated cell sorting (FACS) followed by puromycin or neomycin selection for 2 weeks.
Transwell assay with or without extracellular matrix barrier. For the co-culture assay, MDA-MB-231, MDA-MB-468, MCF-7 and U937 cells cultured in RPMI-1640 supplemented with 10% FBS and 100 U/ml penicillin/streptomycin at a final concentration of 5x10 5 /ml using 6-well insert system with 0.4-µm pores (cat. no. 3450; Corning, Inc., Corning, NY, USA). Breast cancer cell suspension (1 ml) was added to each insert well and 1 ml of U937 cell suspension was added to each lower well. After a 72-h incubation, U937 cells in the lower well were harvested for further examinations. Microscopy images were captured for each well at five randomly picked fields under a microscope with a 10x objective lens, and the number of adhesive cells for each field was quantified. The number of adhesive cells was determined by comparing different breast cancer cell lines and blank control, which was used as reference.
For the Transwell migration assay, GFP expression MDA-MB-231, MCF-7 stable cells were cultured in complete RPMI-1640 medium and RFP expression U937 stable cells cultured in serum-free RPMI-1640 using a 24-well insert system with 5-µm pores (cat. no. 3421; Corning, Inc.). A total of 0.5 ml of 5x10 5 /ml breast cancer cell suspension was added to each lower well, and after a 24-h incubation, 0.5 ml of 5x10 5 /ml U937 cell suspension was added to each insert well. The breast cancer conditioned medium in the lower chamber served as a chemoattractant. After a 72-h incubation, migratory cells were visualized by fluorescence microscopy and images were captured under a fluorescence microscope with a CCD camera. Microscopy images were captured for each well at five randomly picked fields with a 10X objective lens, and the number of migratory cells for each field was quantified. The number of migratory cells was determined by comparing different breast cancer cell lines and blank control, which was used as reference.
The invasion assay was performed similarly to migration assay using 24-well insert system with 8-µm pores (cat. no. 3422; Corning, Inc.) except the inside of the insert was precoated with a thin layer of Matrigel™ Basement Membrane Matrix (BD Biosciences) diluted with serum-free medium to a final concentration of 6 mg/ml. A total of 0.5 ml of 5x10 5 /ml breast cancer cell suspension was added to each lower well, and after a 24-h incubation, 0.5 ml of 5x10 5 /ml U937 cell suspension was added to each insert well. The breast cancer conditioned medium in the lower chamber served as a chemoattractant. After a 72-h incubation, invaded cells were visualized by fluorescence microscopy and images were captured under a fluorescence microscope with a CCD camera. Microscopy images were captured for each well at five randomly picked fields with a 10X objective lens, and the number of invaded cells for each field was quantified. The number of invaded cells was determined by comparing different breast cancer cell lines and blank control, which was used as reference.
Measurement of cytokine production. Cytokine secretion was quantified by Bio-Plex ® cytokine assay. Briefly, conditioned medium samples were obtained after centrifugation to remove cells and their debris and stored at -80˚C until cytokine profiling. We used the fluorescent bead-based detection assay system, with an array of beads in liquid suspension, each containing different ratios of two spectrally distinct fluorophores, thereby assigning a unique spectral identity. The beads, which had been conjugated with a monoclonal antibody specific for a target protein, were incubated with the samples to be tested, washed, followed by addition of a biotinylated detection antibody, washed again, and finally incubated with streptavidin-PE. A wide range of standards (1.78-29,107.00 pg/ml) was used to enable quantitation of the individual cytokines using a Bio-Plex array reader with a dual laser detector and real-time digital signal processing. Cytokine levels were measured using a Multiplex kit (Bio-Rad Laboratories, Inc., San Diego, CA, USA) according to the manufacturer's instructions. Standard curves for each cytokine were generated using the reference concentrations provided in the kit. The plate was run on a Luminex 200 Bio-Plex Instrument (Bio-Rad, Hercules, CA, USA). Raw fluorescence data were analyzed with software using the 5-parameter logistic method. Detailed procedures of the Bio-Plex ® Suspension Array System have been described elsewhere (15) (16) (17) .
Reverse transcription-PCR analysis. Total RNA was isolated from 1x10 6 cells using TRIzol (Invitrogen) according to the manufacturer's instructions. One microgram of total RNA was reverse transcribed using PrimeScript ® RT-PCR Kit (Takara Bio, Dalian, China) primed with oligo(dT). One microliter of cDNA was subjected to PCR amplification using gene-specific primers. PCR products were resolved on a 2% agarose gel and visualized by ethidium bromide staining. Quantitative PCR was carried out using the SYBR ® -Green PCR Master Mix Kit (Takara Bio). Primer sequences are detailed in Table I . The quantification of gene expression was normalized to the expression of GAPDH.
Western blotting assay. For immunoblot analysis, cell lysates containing 50 µg of total protein were separated by electrophoresis on 10% sodium dodecyl sulfate-polyacrylamide gels and electroblotted onto polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). After blocking of the unoccupied sites with 5% skim milk-PBS, the membranes were probed with the desired primary antibodies at 4˚C overnight, followed by incubation with the appropriate HRP-conjugated secondary antibodies, according to the manufacturer's instructions. The primary antibodies were anti-β-actin, anti-CSF1, and the proper dilution of them was according to the instructions. The signal was visualized by ECL Western Blotting Detection Reagents (Pierce Biotechnology, Inc.) and photographed with ImageQuant LAS 4000 (GE Healthcare, Piscataway, NJ, USA). β-actin was used as a loading control.
Breast cancer xenografts. To assess the tumorigenicity in vivo, 8-week-old female non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice were used. Eighteen mice were assigned to six groups equally. A total of 5x10 5 cells suspended in 100 µl PBS were injected orthotopically into the right lower mammary fat pad according to standard injection procedures. Once tumors were palpable, tumor volume (1/2 x length x width 2 ) was monitored every other day for 8 weeks. Tumor growth curves were plotted.
Statistical analysis. The quantitative results are presented as the mean ± standard error of at least three independent experiments. Significant differences were determined with Student's t-test using Excel or GraphPad Prism 5 Demo software (GraphPad Software, Inc., San Diego, CA, USA). P<0.05 was considered statistically significant.
Results
The prevalence of TAM infiltration is significantly higher in hormone-independent breast cancer samples compared with hormone-dependent counterparts. TAMs play an important role in the growth and progression of cancers. CD163 has been reported as a specific surface antigen of M2 macrophages (12) . Herein, we first detected CD163 expression in breast cancer tissues or non-cancer breast tissues by immunohistochemistry. The results showed that the percentage of CD163-positive cells was significantly higher in hormone-independent breast cancers than that in hormone-dependent counterparts and normal breast tissues, in some cases, TAMs may make up as much as 50% of tumor volume. Moreover, the difference was also significant between hormone-independent DCIS and IDC, whereas CD163 expression was hardly detectable in normal breast tissues (Fig. 1) . However, we did not observe a significant difference among tumor size, HER2 expression, lymph node involvement, proliferation index (Ki67) and menstrual status ( Table Ⅱ) .
Impact of TAM infiltration on breast cancer survival.
The impact of TAM infiltration on overall survival (OS) was evaluated in breast cancer patients. Both CD163 and CD204 are specific surface antigens of M2 macrophages, as previously reported (18, 19) . We assessed CD163 and CD204 mRNA expression level in a cohort of 1,117 breast cancer tissue samples (containing tumor stroma) based on publically available gene expression datasets (20) . For CD163 + macrophage frequency, patients were grouped as ʻhighʼ or ʻlowʼ using the lower quartile as a cut-off point; while for CD204 + macrophage frequency, patients were grouped as ʻhighʼ or ʻlowʼ using the median as a cut-off point. Increased expression of CD163 and CD204 was observed in ER-negative patients, and the patients with high density of CD163 + and CD204 + macrophages also showed a poor OS, which was an independent poor prognostic factor for OS ( Fig. 2) .
Hormone-independent breast cancer cells influence monocyte polarization toward TAMs.
The human promonocytic U937 cell line was used as a model to simulate the interaction between monocytes and breast cancer cells in vitro. U937 cells normally grow in suspension and have a smooth surface, as previously reported (21) . However, after co-cultured with hormone-independent breast cancer cell lines MDA-MB-231 and MDA-MB-468 in a 6-well insert system with 0.4-µm pores, they differentiated into M2 macrophages, as evidenced by a thorny morphology, large cell volume and increase in adherence, and increasing expression of surface antigen CD163 and CD204, all of which are characteristics of M2 macrophages. Whereas, no further obvious changes were observed when co-cultured with hormone-dependent MCF-7 cell line ( Fig. 3) .
MDA-MB-231 cancer cells recruit monocyte homing in vitro.
To determine the factors that contributed to monocyte differentiation leaving the vasculature and entering the tumor tissue, we generated stably expressing GFP-puro MDA-MB-231, MCF-7 and RFP with neomycin resistance (RFP-neo) U937 cell lines using lentiviral particles according to the protocol. We performed the Transwell assay without extracellular matrix barrier to study the capability of breast cancer cells to recruit monocytes using a 24-well insert system with 5-µm pores. After co-cultured for 72 h, migratory cells were visualized by fluorescence microscopy and images were captured under a fluorescence microscope. Microscopy images were captured for each well at five randomly picked fields with a 10x objective lens, and the number of migratory cells for each field was quantified (Fig. 4) . We further mimicked the in vivo circumstance applying the Transwell assay with extracellular matrix barrier (BD Biosciences) using a 24-well insert system with 8-µm pores. Our results showed that co-cultured MDA-MB-231 with U937 caused an increase in migration and invasion compared with MCF-7, which indicated that hormone-independent breast cancer cells recruited more monocytes than hormone-dependent breast cancer cells (Fig. 5 ).
Hormone-independent breast cancer cells secrete larger amount of monocyte differentiation-related cytokine CSF1.
The fluorescent bead-based detection assay is a highly sensitive method for profiling multiple cytokines, which has an advantage over conventional enzyme-linked immunosorbent assay (ELISA), which enables analysis of a number of analytes simultaneously (22) . The strong effects of the MDA-MB-231 cells in monocyte recruitment and differentiation led us to inspect their conditioned media (CM) for dissimilarly secreted monocyte chemotaxis and differentiating factors. Among the cytokines tested, there was a significant difference in CSF1 secretion level among different breast cancer cell lines. We found that mean CSF1 level was much higher in MDA-MB-231 cell conditioned medium compared to that of MCF-7 (Fig. 6 ).
Overexpression of CSF1 in MCF-7 fails to rebuild its aggressiveness both in vitro and in vivo while genetic inhibition of CSF1 abrogates TAM infiltration and consequently reduces tumorigenesis in MDA-MB-231.
In order to further study the correlation of CSF1 secretion level with monocyte differentiation and homing, and with tumorigenic ability, we overexpressed CSF1 in MCF-7 cells and generated the stable cell line using lentivirus particles following the protocol. The CSF1-overexpressing MCF-7 stable cells were identified by RT-PCR and western blotting, which showed that CSF1 was overexpressed in MCF-7 artificially (Fig. 7A and B) . However, CSF1 level was not increased in MCF-7 CM (Fig. 7C) .
We co-cultured CSF1-overexpressing MCF-7 stable cells with U937 cells to identify its ability to induce monocyte differentiation using Transwell assay in vitro. We observed that CSF1-overexpressing MCF-7 stable cells did not make U937 cells to differentiate into M2 macrophage (data not shown). This seems to be contradictory superficially, however, as mentioned previously, the active form of CSF1 is an extracellular disulfide-linked homodimer, which is evidenced by our data. No obvious increased CSF1 secretion profile in CSF1-overexpressing MCF-7 stable cell conditioned medium, since we did not envelope the CSF1 plasmid with a proper signal peptide.
Subsequently, we knocked down CSF1 in MDA-MB-231 cells using a series of siRNA sequences (Table Ⅲ ) specifically targeting the CSF1 gene using shRNA lentivirus particles following the protocol. The CSF1-knockdown MDA-MB-231 cells were identified by real-time PCR, which showed that CSF1 was knocked down somewhat in MDA-MB-231 artificially ( Fig. 7D) . We applied the most satisfactory shRNA lentivirus particles (cat. nos. ST3071-A and pLvT742) to generate a stable knockdown cell line for further study. Our data suggested that CSF1-knockdown stable MDA-MB-231 cells secrete much less CSF1 in its CM and thus failed to induce U937 cell differentiation into M2 macrophages.
In an in vivo tumorigenic ability study, 5x10 5 cells suspended in 100 µl PBS were injected orthotopically into the mammary fat pad of 8-week-old female NOD/SCID mice. Similarly, only MDA-MB-231 cell lines form a palpable xenograft tumor successfully in 6 weeks, while being sacrificed in 8 weeks was confirmed again (Fig. 7E ). Both the results of in vitro and in vivo studies confirmed that CSF1 played its role in promoting tumor progression by inducing the differentiation of monocytes.
Discussion
Many pre-clinical and clinical studies demonstrate an inverse correlation between TAM infiltration and patient prognosis indicating a macrophage-supporting role for tumor progression (23) (24) (25) . The recruitment of host stromal cells, such as macrophages and mesenchymal stem cells (MSCs), to the primary tumor is a vital step towards cancer malignancy.
Breast cancer metastasis transforms a local disease which is cured by surgical excision into a systemic disease which responds poorly to available therapies and is the major cause of patient mortality (26) . Multiple stromal cell types, including TAMs, are recruited to the TME and play their roles in metastasis (27, 28) . TAM infiltration is quite common in breast cancer, and sometimes outnumbers the cancer cells in certain cases (29, 30) . The abundance of TAMs in primary breast cancer biopsies is correlated with metastasis and patient mortality (30) (31) (32) . In mouse models, CSF1 secreted by breast cancer cells binds to their cognate receptors, CSF1 receptor (CSF1R) and CCR2 on TAMs, leading to their recruitment to the TME, where they interact with cancer cells to promote invasion and metastasis (33) (34) (35) (36) .
In breast cancer, it is reported that the density of macrophage infiltration and abundance of genes associated with macrophage infiltration are part of a molecular signature that heralds negative prognosis in node-negative, tamoxifen-treated breast carcinomas (37) . Though the expression of M2 macrophage-specific antigen CD163 varied significantly in primary breast cancer, its prevalence has a prognostic impact on OS (38) .
In this study, we applied the U937 cell line as a model to investigate the correlation between monocytes and breast cancer cells. Although the use of human peripheral blood monocyte primary cells should allow stronger conclusions to be drawn, the enrichment of human peripheral blood monocytes involves many ethical issues in our institute. U937 cells have been widely used in macrophage research and have been shown to closely model primary macrophages extracted from whole blood (39) (40) (41) . Moreover, we demonstrated an increased TAM infiltration within ER-negative breast cancer, and confirmed that the density of macrophage infiltration is associated with poor prognosis.
In in vitro models, using co-culture experiments, we also successfully established the differentiation and polarization of monocytes in breast cancer CM as confirmed by morphology and gene expression profile. Our data showed that hormone-independent breast cancer cell CM can induce U937 cell differentiation and then recruit it, whilst in hormone-dependent breast cancer cells no such phenomenon was observed using a panel of representing breast cancer cell lines MCF-7, MDA-MB-231 and MDA-MB-468. Despite this, in the presence of MDA-MB-231 cells, U937 cells significantly increased invasive ability compared to in the presence of MCF-7. This suggests that the specialized M2 macrophages secrete a set of specific proteins that directly destroy the basement, which contribute to cancer invasion and metastasis. We further found that there was a much higher level of CSF1 secretion in MDA-MB-231 CM than in MCF-7, which is required for monocyte differentiation and homing. Consequently, we tentatively depict the progression of hormone-independent breast cancer in Fig. 8 . Identification of this specific protein will aid in developing novel drugs to treat the pro-tumorigenic microenvironment for TNBC. Using our model we have identified a potential treatment to overcome the pro-tumorigenic effects of the macrophage microenvironment.
To the best of our knowledge, this is the first report demonstrating direct experimental evidence that hormone-independent breast cancers demonstrate more aggressively than hormone-dependent breast cancers through secreting CSF1 to educate and recruit monocytes and rebuilding a pro-tumorigenic microenvironment.
In conclusion, TAMs play a critically important role in hormone-independent breast cancer progression, and circulating monocytes are inclined to being recruited and differentiating into TAMs in special tumor niche. New strategies for cancer treatment could emerge from a better understanding of the reciprocal paracrine loop between breast cancer and the microenvironment. Consequently, preventative treatment based on the suppression of monocyte differentiation and homing might be possible. These findings suggest the future possibility of using TAMs as a novel therapeutic target in patients with anti-estrogen resistance and primary TNBC, a tumor type defined by lack of estrogen receptor, progesterone receptor and ERBB2 gene amplification with no effective therapeutic measures at present, although representing ~16% of all breast cancers.
